Remarks

Claims 31, 36, 38, 66, 70, and 74 have been amended as discussed with the Examiner. In particular, the term "agonistic" has been added to claim 31, the phrase "and wherein said anti-TR17 antibody inhibits B cell proliferation" has been added to claim 36, and the phrase "and wherein said anti-TR17 antibody inhibits immunoglobulin production" has been added to claim 38. Claims 66, 70, and 74 have been amended to correct a clerical error in the preamble to reference "the method" of the independent claim, rather than "the antibody." The amendments are fully supported by the application as originally filed, and thus no new matter has been added.

As discussed with the Examiner, claims 64-75 appear to have been withdrawn as a result of the clerical error noted above. However, now that this error has been rectified, these are dependent claims directed to the methods of the elected group, and they should be rejoined and examined with independent claims 31, 36, and 38.

Claims 31, 36, 38, and 64-77 are pending. Based on the conversation with the Examiner, Applicants believe that the present amendments place the claims in condition for allowance.

I. Rejection Under 35 U.S.C. § 112, First Paragraph

Claims 31, 36 and 38 were rejected under 35 U.S.C. § 112, first paragraph for allegedly containing subject matter which was not described in the specification in such a manner as to reasonably convey to one skilled in the art that the inventor(s), at the time the application was filed had possession of the claimed invention. In particular, the Examiner asserts that the claims do not define TR17 by structure or sequence.

In response, Applicants respectfully disagree and traverse. As discussed with the Examiner, claims 31, 36, and 38 each require that "said TR17 protein is encoded by a polynucleotide that encodes amino acids 1 to 293 of SEQ ID NO:2." Unlike the situation in *Noelle v. Lederman*, the antigen in the present case is <u>fully characterized</u> by reference to its encoded sequence. While the Examiner correctly notes that the claims encompass methods of using a genus of antibodies to TR17, these antibodies are also required to inhibit B cell proliferation or immunoglobulin production. Thus, not only is the antigen defined by a specific sequence, the antibodies are also defined by particular functional properties disclosed in the specification.

Application No.: 09/961,376

Page 5

Docket No.: PF524P1

Feb-17-05 07:31pm

Since one skilled in the art would have readily recognized that the inventors were in possession of the invention as presently claimed as of the filing date of the application. Applicants respectfully assert that the written description rejection has been obviated. Accordingly, the instant rejection should be reconsidered and withdrawn.

II. Rejection Under 35 U.S.C. § 112, Second Paragraph

The Examiner has rejected claims 31, 36, and 38 (and claims that depend therefrom), alleging that the phrase "anti-TR17 antibody" is indefinite; the Examiner indicated that the phrase "agonistic anti-TR17 antibody" would be acceptable.

In response, claims 31, 36, and 38 have been amended to recite the term "agonistic" as requested by the Examiner. Accordingly, Applicants believe that the instant rejection has been obviated and should be reconsidered and withdrawn.

Conclusion

Entry of the above amendment is respectfully solicited. The Examiner is invited to call the undersigned at the phone number provided below if any further action by Applicants would expedite the allowance of this application.

If there are any fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425. If a fee is required for an additional extension of time under 37 C.F.R. § 1.136, such an extension is requested and the appropriate fee should also be charged to our Deposit Account.

Dated: February 17, 2005

Respectfully submitted,

Mark J. Hyman

Registration No.: 46,789

HUMAN GENOME SCIENCES, INC.

Intellectual Property Dept. 14200 Shady Grove Road Rockville, Maryland 20850

(240) 314-1224

KKH/MS/ba (MJH)

Application No.: 09/961,376

Page 6

Docket No.: PF524P1

Attorney Docket No.: PF524P1

Feb-17-05 07:31pm From-HGS INTELLECTUAL PROPERTY DEPT

PTC/SB/97 (09-04)
Approved for use through 07/31/2006. QMB 0851-0031
U. S. Patent and Tragemark Office; U.S. DEPARTMENT OF COMMERCE

Under the Progresson Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid QMB control number.

Application No. (if known): 09/961,376

OD

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the Unite States Patent and Trademark Office.			

 100:00:1
Data
Date

February 17, 2005

Mu	W_		
7	Signature		
Mark J. Hyman			
Typed or printed name of person signing Certificate			
46. 789	240-314-7224		
Registration Number, if applic	cable Telephone Number		

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Response and Amendment Under 37 C.F.R. § 1.116 (6 pages)